Skip to content

Study · Animal study (in vivo) · mouse · 2024

6 results

Humanin's impact on pain markers and neuronal viability in diabetic neuropathy model.

Kelestemur MM, Bulut F, Bılgın B, Hekım MG, Adam M, Ozcan S, Beker MC, Kaya Tektemur N, Tekin S, Canpolat S, Ozcan M

Archives of physiology and biochemistry10 Apr 2024Cited by 6 (Europe PMC)

PMID38599217 (opens in a new tab)DOI10.1080/13813455.2024.2336922 (opens in a new tab)PepBankPUB-38599217
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, humanin significantly reduced the diabetes-induced elevation of NMDA in dorsal root ganglia.

    In plain wordsIn diabetic mice, humanin lowered a pain-related protein that diabetes had raised.

    Peptide
    Humanin
    Outcome
    DecreaseNMDA expression in DRG
    Study

    mousen = 10

    Diabetic mice dorsal root ganglia
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    4 mg/kg · 15 daysAs given in this study (mouse).

    Source sentences

    Summary
    Humanin significantly reduced the elevated expression of NMDA, IL-1β, TRPV1, and substance P induced by diabetes (p < .05).
    1 context sentence
    Summary · context
    In vivo experiments involved 15 days of HN administration (4 mg/kg) to diabetic mice (n = 10).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, humanin significantly reduced the diabetes-induced elevation of IL-1β in dorsal root ganglia.

    In plain wordsIn diabetic mice, humanin lowered a pain-related inflammatory protein that diabetes had raised.

    Peptide
    Humanin
    Outcome
    DecreaseIL-1β expression in DRG
    Study

    mousen = 10

    Diabetic mice dorsal root ganglia
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    4 mg/kg · 15 daysAs given in this study (mouse).

    Source sentences

    Summary
    Humanin significantly reduced the elevated expression of NMDA, IL-1β, TRPV1, and substance P induced by diabetes (p < .05).
    1 context sentence
    Summary · context
    In vivo experiments involved 15 days of HN administration (4 mg/kg) to diabetic mice (n = 10).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, humanin significantly reduced the diabetes-induced elevation of TRPV1 in dorsal root ganglia.

    In plain wordsIn diabetic mice, humanin lowered a pain-related protein that diabetes had raised.

    Peptide
    Humanin
    Outcome
    DecreaseTRPV1 expression in DRG
    Study

    mousen = 10

    Diabetic mice dorsal root ganglia
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    4 mg/kg · 15 daysAs given in this study (mouse).

    Source sentences

    Summary
    Humanin significantly reduced the elevated expression of NMDA, IL-1β, TRPV1, and substance P induced by diabetes (p < .05).
    1 context sentence
    Summary · context
    In vivo experiments involved 15 days of HN administration (4 mg/kg) to diabetic mice (n = 10).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, humanin significantly reduced the diabetes-induced elevation of substance P in dorsal root ganglia.

    In plain wordsIn diabetic mice, humanin lowered a pain-related protein that diabetes had raised.

    Peptide
    Humanin
    Outcome
    DecreaseSubstance P expression in DRG
    Study

    mousen = 10

    Diabetic mice dorsal root ganglia
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    4 mg/kg · 15 daysAs given in this study (mouse).

    Source sentences

    Summary
    Humanin significantly reduced the elevated expression of NMDA, IL-1β, TRPV1, and substance P induced by diabetes (p < .05).
    1 context sentence
    Summary · context
    In vivo experiments involved 15 days of HN administration (4 mg/kg) to diabetic mice (n = 10).
  5. 05LabIn vitro (cells)Efficacy outcome

    In dorsal root ganglion neurons, humanin treatment increased cellular viability.

    In plain wordsIn lab-grown nerve cells, humanin treatment increased cell survival.

    Peptide
    Humanin
    Outcome
    IncreaseCellular viability of DRG neurons
    Study

    n: not reported in source

    DRG neurons
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, HN treatment increased cellular viability in DRG neurons through JAK2/STAT3 pathway activation (p < .05).
    1 context sentence
    Summary · context
    In vitro experiments explored HN's impact on apoptosis and cellular viability, focusing on the JAK2/STAT3 pathway.
  6. 06LabIn vitro (cells)Mechanism

    In dorsal root ganglion neurons, humanin treatment increased viability through activation of the JAK2/STAT3 pathway.

    In plain wordsIn lab-grown nerve cells, humanin increased survival through a cell signaling pathway called JAK2/STAT3.

    Peptide
    Humanin
    Outcome
    IncreaseJAK2/STAT3 pathway activation
    Study

    n: not reported in source

    DRG neurons
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, HN treatment increased cellular viability in DRG neurons through JAK2/STAT3 pathway activation (p < .05).
    1 context sentence
    Summary · context
    In vitro experiments explored HN's impact on apoptosis and cellular viability, focusing on the JAK2/STAT3 pathway.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.